EventsThe 4th International Electronic Conference on Cancers
Published
This submission belongs to the session Session C. Cancer Immunology and Immunotherapy of the event The 4th International Electronic Conference on Cancers
Published date
27 Mar, 2024
Academic Editor
author-avatarVasso Apostolopoulos
Citation
Ramya Ephraim, Sarah Fraser, Jeannie Devereux, Rhian Stavely, Jack Feehan, Rajaraman Eri, Kulmira Nurgali, Vasso Apostolopoulos, Differential Gene Expression of Checkpoint Markers and Cancer Markers in Mouse Models of Spontaneous Chronic Colitis, in Proceedings of The 4th International Electronic Conference on Cancers, 6 March–8 March 2024, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

Differential Gene Expression of Checkpoint Markers and Cancer Markers in Mouse Models of Spontaneous Chronic Colitis

Sarah Fraser 1
Jeannie Devereux 1
Rhian Stavely 2
Jack Feehan 1,3
image
Kulmira Nurgali 1,5,6
image
1. Institute for Health and Sport, Victoria University, Melbourne, Australia, Australia
2. Department of Pediatric Surgery, Pediatric Surgery Research Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA, USA
3. Immunology Program, Australian Institute of Musculoskeletal Science (AIMSS), Melbourne, Victoria, Australia
4. School of Science/STEM, RMIT University, Australia, Australia
5. Department of Medicine Western Health, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia
6. Regenerative Medicine and Stem Cells Program, Australian Institute of Musculoskeletal Science (AIMSS), Melbourne, Victoria, Australia
7. Immunology Program, Australian Institute of Musculoskeletal Science (AIMSS), Melbourne, Victoria, Australia, Australia
8. Institute for Health and Sport, Victoria University, Melbourne, Australia
Abstract

The presence of checkpoint markers in cancer cells aids in immune escape. The identification of checkpoint markers and early cancer markers is of utmost importance to gain clarity regarding the relationship between colitis and progressive inflammation leading to cancer. Herein, the gene expression levels of checkpoint makers, cancer-related pathways, and cancer genes in colon tissues of mouse models of chronic colitis (Winnie and Winnie-Prolapse mice) using next-generation sequencing are determined. Winnie mice are a result of a Muc2 missense mutation. The identification of such genes and their subsequent expression and role at the protein level would enable novel markers for the early diagnosis of cancer in IBD patients. The differentially expressed genes in the colonic transcriptome were analysed based on the Kyoto Encyclopedia of Genes and Genomes pathway. The expression of several oncogenes is associated with the severity of IBD, with Winnie-Prolapse mice expressing a large number of key genes associated with development of cancer. This research presents a number of new targets to evaluate for the development of biomarkers and therapeutics.

Keywords
checkpoint markers
cancer cells
colitis
progressive inflammation
Muc2
IBD
biomarkers
therapeutics
Application of a Preoperative Nomogram Based on the Gastric Cancer Integrated Oxidative Stress Score in Predicting Overall Survival and Chemotherapy Benefits in Gastric Cancer Patients
Cholinergic signaling influences the expression of immune checkpoint inhibitors, PD-L1 and PD-L2, and tumor hallmarks in human colorectal cancer tissues and cell lines